Thymagen

What is Thymagen?

Thymagen (also known as Thymogen) is a synthetic dipeptide composed of L-glutamic acid and L-tryptophan (Glu-Trp, single-letter code: EW). It was isolated from the calf-thymus extract Thymalin by reverse-phase HPLC in the 1980s by Vladimir Khavinson and Vyacheslav Morozov, working in Khavinson's bioregulation laboratory at the Military Medical Academy in Leningrad; the St. Petersburg Institute of Bioregulation and Gerontology came later, in 1992. It was the first defined active peptide identified in Thymalin, which Khavinson has described as containing more than 50 peptides. Vilon (Lys-Glu) is often paired with it, but was first reported as a newly designed synthetic dipeptide; the Khavinson group reported detecting Lys-Glu in Thymalin only in 2020. While Thymalin is a complex extract containing multiple thymic factors, Thymagen represents its isolated immunostimulatory dipeptide, synthesized for pharmaceutical use. It was registered as a drug in Russia in 1990 and is sold there without a prescription as an intramuscular solution, a nasal spray, a topical cream, and a powder for an oral gel. The same molecule, under the international name oglufanide (code IM862), was developed by the US company Cytran and tested in American and British cancer trials from the late 1990s to the mid-2000s. Notably, the all-D versions of the dipeptide have the opposite effect in laboratory tests, suppressing immune and blood-forming cells instead of stimulating them. One of them, gamma-linked D-Glu-D-Trp, became the Russian immunosuppressant Thymodepressin (registered 2008) — strictly not the exact mirror image of Thymogen, because its amino acids are joined through glutamic acid's side-chain carboxyl rather than the usual alpha bond.

What Thymagen Is Investigated For

Thymagen is investigated primarily for immune restoration in aging and immunodeficiency, T-cell differentiation support, respiratory infection prevention, and broader anti-aging and anti-carcinogenic claims within the Khavinson bioregulator framework. The strongest available evidence is the 30+ years of registered Russian pharmaceutical use since 1990 — including a double-blind, randomized, placebo-controlled study in elderly patients given nasal thymogen for seven days before abdominal tumor surgery, which reported fewer postoperative complications, a type 1 diabetes study reporting T-lymphocyte differentiation activation, and a military cohort study showing reduced respiratory infection morbidity with intranasal thymogen. A long-duration rat study also demonstrated extended maximum lifespan and reduced spontaneous tumor incidence. The honest caveats are substantial. Western-standard trials were run only in cancer, under the name oglufanide (IM862): a 202-patient randomized, double-blind, placebo-controlled Phase III trial in AIDS-related Kaposi's sarcoma found no benefit over placebo, and a placebo-controlled prostate cancer trial was also negative. The Russian immune indications have never been tested in Western trials, human pharmacokinetic data have not been published, and the proposed mechanism of direct DNA and histone binding by a dipeptide rests on molecular modeling from the Khavinson group without independent confirmation. The D-enantiomer (D-Glu-D-Trp) has opposite immunosuppressive activity, making stereochemical purity critical — research-chemical supply cannot be assumed equivalent to Russian pharmaceutical-grade product.

History & Discovery

Thymagen — also widely known as Thymogen — emerged from the Khavinson and Morozov program that produced the parent Thymalin extract — at the time based in Khavinson's bioregulation laboratory at the Military Medical Academy in Leningrad, founded in 1982; the St. Petersburg Institute of Bioregulation and Gerontology came later, in 1992. In the 1980s, after years of clinical work with the heterogeneous calf-thymus preparation, the group used reverse-phase HPLC to fractionate Thymalin and identified the dipeptide L-Glu-L-Trp as a primary immunostimulatory component. They synthesized it as a chemically defined pharmaceutical, registering it in Russia in 1990 in three formulations: intramuscular injection, nasal spray, and topical cream. Thymagen is one of the more concretely defined entries in the Khavinson catalog — a synthesized dipeptide rather than a heterogeneous extract — and it has the additional curiosity that its D-enantiomer (D-Glu-D-Trp, marketed as Thymodepressin) reportedly has the opposite biological activity, an unusual property in peptide pharmacology. The molecule also had a Western chapter. The US company Cytran, holding patents that name Khavinson and Morozov as inventors, developed it as IM862 — later given the international name oglufanide — and from the late 1990s to the mid-2000s ran nasal-dose trials in AIDS-related Kaposi's sarcoma and in ovarian, colorectal, kidney, and prostate cancer. An early randomized study reported a 36% response rate in Kaposi's sarcoma, but the 202-patient Phase III trial published in 2005 found no benefit over placebo, with the authors concluding that effective HIV therapy probably explained the earlier responses. Rights passed to Australia's Implicit Bioscience in 2005. The dipeptide is not approved by any Western regulator. Indexed clinical literature in major databases is sparse; most evidence remains within the Russian research network, and independent Western replication is limited.

How It Works

Thymagen is a two-amino-acid peptide that helps restore immune function by supporting the maturation and activation of T-cells — the immune cells trained in the thymus gland. As the thymus shrinks with age, immune function declines. Thymagen may help compensate by activating T-cell differentiation, reducing immune cell death (apoptosis), enhancing the activity of pathogen-engulfing cells (neutrophils and macrophages), and dampening excessive inflammatory signaling.

Thymagen (L-Glu-L-Trp) exerts immunomodulatory effects through multiple pathways. It activates T-cell differentiation and enhances T-cell recognition of peptide-MHC complexes. The dipeptide shifts the balance of the signaling molecules cAMP and cGMP inside lymphocytes; small guinea-pig studies from 1990 and 1991 reported that it mainly boosted cGMP production and increased, rather than decreased, the activity of the enzymes that break these molecules down. In monocyte/macrophage THP-1 cell models, Thymagen (as part of the Khavinson peptide panel) increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases while inhibiting TNF and pro-inflammatory IL-6 expression under LPS stimulation, acting as a natural inducer of TNF tolerance. It reduces monocyte adhesion to activated endothelial cells. In spleen cell studies, Thymagen activates B-lymphocytes through inhibition of apoptosis and stimulation of proliferation. In immune cells from human blood stimulated with bacterial LPS, EW alone cut TNF-alpha release about 5-fold but did not significantly lower IL-1-beta; the frequently quoted 1.4-to-6.0-fold range covers Thymalin, EW, and KE combined. A computer-modeling analysis flagged the ACE2 gene as a possible EW target, but EW has not been shown to reduce ACE2 expression; a separate German laboratory found that EW inhibits the related enzyme ACE. At the epigenetic level, the Khavinson group proposes that Glu-Trp binds DNA promoter regions and opens up chromatin, based on a molecular-docking study; the group's histone-binding experiments tested other short peptides, not Glu-Trp. Other work points to a cell-surface target instead: a related Glu-Trp isomer binds mouse macrophages and thymocytes with high affinity, thymogen blocks that binding, and the binding disappears after the cells are treated with the protein-digesting enzyme trypsin. It also activates neutrophil chemotaxis and phagocytic activity. In US studies of oglufanide, the anti-tumor effect in mice depended on natural killer cells and perforin rather than direct toxicity to tumor cells, and in a kidney cancer trial blood VEGF levels fell after 4 and 8 weeks. The anti-angiogenic label rests mostly on indirect findings like these; an independent German laboratory found EW blocked blood-vessel sprouting in only some assays.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Thymagen:

• 01Independent replication of the core Russian claims. Western laboratories have studied the molecule — US and UK cancer trials, German and Japanese preclinical work — but none has tested the Russian immune and anti-infection claims, and the large Western trial that was run came out negative.
• 02Modern blinded randomized trials of the Russian indications — immune correction, respiratory infection prevention, anti-aging — in Western populations. The only Western randomized trials, in cancer under the name oglufanide, were negative, and an Australian hepatitis C trial begun in 2007 has no indexed results.
• 03Formal pharmacokinetics in humans — absorption (particularly across nasal mucosa), distribution, metabolism, and clearance have not been characterized by Western standards.
• 04Mechanism specificity — the proposed mechanism of direct DNA and histone binding by a dipeptide is supported by molecular modeling from the Khavinson group but has not been independently replicated outside that program.
• 05Long-term safety with cumulative repeated courses across multiple years.
• 06Cancer safety — in the US Phase III Kaposi's sarcoma trial, patients on IM862 progressed sooner than those on placebo (median 16 versus 35 weeks, p = 0.012). Whether that was chance or a real effect was never resolved, and Russian observational data do not address it.
• 07The actual molecular target — high-affinity binding to immune cells that is lost after trypsin treatment suggests a cell-surface protein receptor, which has never been identified, while the Khavinson group favors direct DNA binding based on computer docking.

Forms & Administration

In Russia, Timogen is sold as an intramuscular solution (adult label dose 100 mcg once daily for 3 to 10 days), a metered nasal spray, a topical cream, and a powder for an oral gel. US cancer trials of the same molecule used far larger nasal doses: 5 mg every other day for Kaposi's sarcoma and 20 mg three times daily for kidney cancer. Outside Russia, it is available as a research peptide for subcutaneous injection. The Russian label allows a repeat course no sooner than one month after the last, with up to four courses a year. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Claims for Thymagen's broader anti-aging, lifespan-extension, and cancer-prevention effects exceed what the evidence base, dominated by single-program Russian research, can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical supply outside Russian pharmaceutical channels is not authorized for human use, and stereochemical purity cannot be assumed.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Thymagen Is NOT For

Drug & Supplement Interactions

Documented clinical drug interactions for Thymagen are limited; no formal interaction studies meeting Western standards have been published. Theoretical class concerns mirror Thymalin: concurrent use with immunosuppressive agents (corticosteroids at immunosuppressive doses, calcineurin inhibitors, T-cell-targeted biologics) would be expected to oppose Thymagen's intended T-cell-supportive activity and is not consistent with the prescribing rationale for those agents. Russian clinical literature describes adjunctive use with antibiotics, antiviral therapy, and tuberculostatic regimens without flagged interactions, but these reports do not meet modern interaction-study standards. Patients on any regular medication should disclose use to their prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions